Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cancer.Net. Lung cancer - non-small cell: statistics. 2022 [Accessed 2023 Nov 16]. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
   Google Scholar
• Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. [2022 Apr 20];40(12):1356–1384. doi: 10.1200/JCO.21.02528
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. [2017 Jul 1];28(suppl_4):iv1–iv21. doi: 10.1093/annonc/mdx222
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN guidelines version 5.2022. Non-small cell lung cancer. [Accessed 2022 Nov 16]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• Clinicaltrials.gov. A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable non-small cell lung cancer (AEGEAN). [Accessed 2022 Jul 5]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03800134.
   Google Scholar
• Clinicaltrials.gov. A neoadjuvant study of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in early stage non-small cell lung cancer (NSCLC) (CheckMate 816). [Accessed 2022 Jul 5]. Available at: https://clinicaltrials.gov/ct2/show/NCT02998528.
   Google Scholar
• Clinicaltrials.gov. A study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical removal and adjuvant treatment with nivolumab or placebo for participants with surgically removable early stage non-small cell lung cancer. [Accessed 2022 Jul 7]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT04025879.
   Google Scholar
• Clinicaltrials.gov. A study of neoadjuvant atezolizumab plus chemotherapy versus placebo plus chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer (IMpower030). [Accessed 2022 Jul 7]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03456063.
   Google Scholar
• Clinicaltrials.gov. Efficacy and safety of pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (MK-3475-671/KEYNOTE-671). [Accessed 2022 Jul 7]. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03425643.
   Google Scholar
• FDA. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. [Accessed 2022 Aug 23]. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung.
   Google Scholar
• Lux MP, Ciani O, Dunlop WCN, et al. The impasse on overall survival in oncology reimbursement decision-making: how can we resolve this? Cancer Manag Res. 2021;13:8457–8471. doi: 10.2147/CMAR.S328058
   PubMed Web of Science ®Google Scholar
• FDA. Clinical trial endpoints for the approval of cancer drugs and biologics. Guidance For Industry. 2018 [Accessed 2022 Jul 26]. Available at: https://www.fda.gov/media/71195/download.
   Google Scholar
• National Institute for Health and Care Excellence. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. [Accessed 2022 Aug 23]. Available at: https://www.nice.org.uk/guidance/ta761/resources/osimertinib-for-adjuvant-treatment-of-egfr-mutationpositive-nonsmallcell-lung-cancer-after-complete-tumour-resection-pdf-82611430864837.
   Google Scholar
• National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. [Accessed 2022 Sep 29]. Available at: https://www.nice.org.uk/guidance/ta823.
   Google Scholar
• Risk of bias info. [Accessed 2022 Nov 28]. Available at: https://www.riskofbias.info/welcome.
   Google Scholar
• Cochrane Methods. Risk of bias in non-randomized studies - of interventions (ROBINS-I). [Accessed 2022 Nov 28]. Available at: https://methods.cochrane.org/bias/risk-bias-non-randomized-studies-interventions.
   Google Scholar
• Shameer K, Zhang Y, Jackson D, et al. Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis. Front Oncol. 2021;11:672916. doi: 10.3389/fonc.2021.672916
   PubMedGoogle Scholar
• Ciani O, Buyse M, Drummond M, et al. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017 Mar;20(3):487–495. doi: 10.1016/j.jval.2016.10.011
   PubMed Web of Science ®Google Scholar
• Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology assessment reports. Health Technol Assess. 2009;13(8):8. doi: 10.3310/hta13080
   Web of Science ®Google Scholar
• Schürmann C, Sieben W. Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches. Stat Med. 2016;35(7):1049–1062. doi: 10.1002/sim.6778
   PubMed Web of Science ®Google Scholar
• Xie W, Halabi S, Tierney JF, et al. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectr. 2019 Mar;3(1):kz002. doi: 10.1093/jncics/pkz002
   Web of Science ®Google Scholar
• Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. [2021 Dec 21];375:e066381. doi: 10.1136/bmj-2021-066381
   PubMedGoogle Scholar
• Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [clinical trial, phase III comparative study randomized controlled trial research support, N.I.H., extramural research support, non-U.S. Gov’t]. Lancet. [2009 Aug 1];374(9687):379–386. doi: 10.1016/S0140-6736(09)60737-6
   PubMed Web of Science ®Google Scholar
• Chen Z, Luo Q, Hong J, et al. Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer. Onco Targets Ther. 2013;6:645–650. doi: 10.2147/OTT.S44503
   PubMed Web of Science ®Google Scholar
• Katakami N, Tada H, Mitsudomi T, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. [2012 Dec 15];118(24):6126–6135. doi: 10.1002/cncr.26689
   PubMed Web of Science ®Google Scholar
• Thomas M, Rube C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008 Jul;9(7):636–648. doi: 10.1016/S1470-2045(08)70156-6
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. [2007 21 Mar];99(6):442–450. doi: 10.1093/jnci/djk093
   PubMedGoogle Scholar
• Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. [2010 1 Jul];28(19):3138–3145. doi: 10.1200/JCO.2009.27.6204
   PubMed Web of Science ®Google Scholar
• Pisters KM, Vallieres E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology group trial S9900, an intergroup, randomized, phase III trial [clinical trial, phase III multicenter study randomized controlled trial research support, N.I.H., extramural research support, non-U.S. Gov’t]. J Clin Oncol. [2010 Apr 10];28(11):1843–1849. doi: 10.1200/JCO.2009.26.1685
   PubMed Web of Science ®Google Scholar
• Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet. [2007 Jun 9];369(9577):1929–1937. doi: 10.1016/S0140-6736(07)60714-4
   PubMed Web of Science ®Google Scholar
• Brandt WS, Yan W, Zhou J, et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2019 Feb;157(2):743–753.e3. doi: 10.1016/j.jtcvs.2018.09.098
   PubMed Web of Science ®Google Scholar
• Counago F, Rodriguez de Dios N, Montemuino S, et al. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: a multi-institutional study by the oncologic group for the study of lung cancer (Spanish radiation Oncology Society). Lung Cancer. 2018 Apr;118:119–127.
   PubMed Web of Science ®Google Scholar
• Vyfhuis MAL, Burrows WM, Bhooshan N, et al. Implications of pathologic complete response beyond mediastinal nodal clearance with high-dose neoadjuvant chemoradiation therapy in locally advanced, non-small cell lung cancer. Int J Radiat Oncol Biol Phys. [2018 1 Jun];101(2):445–452. doi: 10.1016/j.ijrobp.2018.02.003
   PubMed Web of Science ®Google Scholar
• Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for advanced non–small cell lung cancer: a decade of progress. Am Soc Clin Oncol Educ Book. 2021 Mar;41(41):e105–e127. doi: 10.1200/EDBK_321483
   Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. [2022 May 26];386(21):1973–1985. doi: 10.1056/NEJMoa2202170
   PubMed Web of Science ®Google Scholar
• Provencio M, Serna R, Nadal E, et al. Nivolumab + chemotherapy vs chemotherapy as neoadjuvant treatment for resectable IIIA-B NSCLC. Progression-free survival and overall survival results from the phase 2 NADIM II trial [oral presentation]. Presented at the World Conference on Lung Cancer; 2022 Aug 6–9; Vienna, Austria.
   Google Scholar
• Waser N, Adam A, Schweikert B, et al. Pathologic response as early endpoint for survival following neo-adjuvant therapy in resectable non-small cell lung cancer: systematic literature review and meta-analysis. Presented At The European Society For Medical Oncology Virtual Congress. [19–21 Sep 2020];31:S806. doi: 10.1016/j.annonc.2020.08.116
   Google Scholar
• Spineli LM, Pandis N. Prediction interval in random-effects meta-analysis. Am J Orthod Dentofacial Orthop. 2020 Apr;157(4):586–588. doi: 10.1016/j.ajodo.2019.12.011
   PubMed Web of Science ®Google Scholar